Condition

Lung Cancer Stage III

ClinicalTrials.gov condition label

Clinical trials19

Recruiting6

Common interventions25

Lead sponsors shown15

Clinical trials

19 shown

Bovine Reinforcement in Stomach, Colorectal and Lung OperationNCT06968221 · 2025-05-01

Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.NCT06563999 · 2024-11-01

Clinical Validation and Benchmarking of Top Performing ctDNA Diagnostics - Stage III NSCLCNCT06111807 · 2023-11-10

Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With SurgeryNCT04991025 · 2022-10-19

Neoadjuvant IBI308, Bevacizumab, Plus Pemetrexed and Carboplatin Followed by Surgery in Unresectable Stage III NSCLCNCT03872661 · 2019-03-01

COr Loco-regional Advanced Lung Cancer Treated With Chemo-radiotherapy (COLA)NCT05258448 · 2015-08-01

A Trial of AN0025 With Chemoradiation Therapy in Stage III NSCLC ParticipantsNCT05358691 · 2024-11-01

Induction Chemo-Nivo in Unresectable Stage III NSCLCNCT06003075 · 2023-12-13

Enabling Remote Access to Breathe Easier: A Novel Approach to Improve Symptom ManagementNCT06060964 · 2023-10-02

Radiotherapy Combined With Almonertinib for Stage III EGFR-Mutated Lung CancerNCT05994339 · 2023-09-01

Prognostic Value of Combined Approach Based on KEAP1/NFE2L2 Mutations and Pre-therapeutic FDG-PET/CT Radiomic Analysis in Advanced Non-small-cell Lung Cancer PDL1 ≥ 50% Treated With Pembrolizumab (PEMBROMIC)NCT05996263 · 2023-08-01

Developing Circulating and Imaging Biomarkers Towards Personalised Radiotherapy in Lung CancerNCT06086574 · 2023-03-24

Resilience Measurement in Older Adults With Late-Stage Lung CancerNCT04825912 · 2021-05-03

Cardiotoxicity in Locally Advanced Lung Cancer Patients Treated With Chemoradiation TherapyNCT04305613 · 2020-09-14

ACTIVE_NOT_RECRUITING

Phase II Concurrent Durvalumab and Radiotherapy for for Stage III Non-Small Cell Lung CancerNCT04003246 · 2020-04-03

Self-System Therapy for Older Adults With Lung CancerNCT04057196 · 2020-04-02

Radiomic Signature as Predictive Marker of Response to Chemoradiation and Durvalumab in Stage III NSCLC.NCT04364776 · 2020-01-15

Thoracic Radiotherapy Plus EGFR-TKI for Stage III EGFR-mutant Lung AdenocarcinomaNCT07857694 · 2020-01-01

Use of High Dose Radiation Followed by Chemotherapy and Radiation to Treat Locally Advanced NSCLCNCT03141359 · 2017-05-12

ACTIVE_NOT_RECRUITING

Common interventions

Leading sponsors

Duke University2 Laibin People's Hospital2 Sun Yat-sen University2 Abramson Cancer Center at Penn Medicine1 Fondazione IRCCS Policlinico San Matteo di Pavia1 Memorial Sloan Kettering Cancer Center1 Odense University Hospital1 Ralph G Zinner1 Rutgers, The State University of New Jersey1 Shanghai Cingularbio Co. Ltd1 University Hospital, Brest1 University Medical Center Groningen1 University of Manchester1 University of South Carolina1 University of Texas Southwestern Medical Center1

Trial status mix

RECRUITING6

UNKNOWN5

COMPLETED4

ACTIVE_NOT_RECRUITING2

TERMINATED1

WITHDRAWN1

Phase mix

PHASE27

NA2

PHASE32

EARLY_PHASE11

PHASE11

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.